Why the article that led to the widespread use of hydroxychloroquine in COVID-19 should be retracted

Affiliations

¹ Department of Intensive Care Medicine, CHR Metz-Thionville, 57530 Ars-Laquenexy, France. Electronic address: d.barraud@chr-metz-thionville.fr.
² Media and Information Technology, Linköping University, 581 83 Norrköping, Sweden.
³ Harbers Bik LLC, San Francisco, CA, USA.
⁴ 67000 Strasbourg, France.
⁵ Department of Forensic Medicine and Pathology, University Rouen, 76031 Rouen cedex, France.
⁶ Essaouira, Morocco.
⁷ Department of Plant Molecular Biology, Faculty of Biology and Medicine, University of Lausanne (UNIL), CH-1015 Lausanne, Switzerland.
⁸ Inserm, département de santé publique, institut Pierre-Louis d'épidémiologie et de santé publique, centre de pharmacoépidémiologie, Sorbonne université, hôpital Pitié-Salpêtrière, AP-HP, 75231 Paris, France.
⁹ IPLESP, Sorbonne université, hôpital Saint-Antoine, AP-HP, 75231 Paris, France.
¹⁰ School of Medicine, université Paris-Cité, 75106 Paris, France.
¹¹ Service de pharmacologie CHU de Bordeaux, université de Bordeaux, 33600 Pessac, France.
¹² Institute of Biology, University of Neuchâtel, 2000 Neuchâtel, Switzerland; University of Neuchâtel, Hospital Network of Neuchâtel, 2000 Neuchâtel, Switzerland.
¹³ 06000 Nice, France.

Damien Barraud et al. Therapie. 2023 Jul-Aug.

. 2023 Jul-Aug;78(4):437-440.

doi: 10.1016/j.therap.2023.06.001. Epub 2023 Jun 2.

¹ Department of Intensive Care Medicine, CHR Metz-Thionville, 57530 Ars-Laquenexy, France. Electronic address: d.barraud@chr-metz-thionville.fr.
² Media and Information Technology, Linköping University, 581 83 Norrköping, Sweden.
³ Harbers Bik LLC, San Francisco, CA, USA.
⁴ 67000 Strasbourg, France.
⁵ Department of Forensic Medicine and Pathology, University Rouen, 76031 Rouen cedex, France.
⁶ Essaouira, Morocco.
⁷ Department of Plant Molecular Biology, Faculty of Biology and Medicine, University of Lausanne (UNIL), CH-1015 Lausanne, Switzerland.
⁸ Inserm, département de santé publique, institut Pierre-Louis d'épidémiologie et de santé publique, centre de pharmacoépidémiologie, Sorbonne université, hôpital Pitié-Salpêtrière, AP-HP, 75231 Paris, France.
⁹ IPLESP, Sorbonne université, hôpital Saint-Antoine, AP-HP, 75231 Paris, France.
¹⁰ School of Medicine, université Paris-Cité, 75106 Paris, France.
¹¹ Service de pharmacologie CHU de Bordeaux, université de Bordeaux, 33600 Pessac, France.
¹² Institute of Biology, University of Neuchâtel, 2000 Neuchâtel, Switzerland; University of Neuchâtel, Hospital Network of Neuchâtel, 2000 Neuchâtel, Switzerland.
¹³ 06000 Nice, France.

No abstract available

Keywords: COVID-19; Clinical research; Ethics; Hydroxychloroquine; Retraction.

References

1. Gautret P., Lagier J.C., Parola P., Hoang V.T., Meddeb L., Mailhe M., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56:105949. - PMC - PubMed
1. Gautret P., Hoang V.T., Chaudet H., Lagier J.C., Raoult D. Response to uncertain effect of hydroxychloroquine and azithromycin on SARS-CoV-2 viral load. Int J Antimicrob Agents. 2021;57:106244. - PMC - PubMed
1. Roustit M., Guilhaumou R., Molimard M., Drici M.D., Laporte S., Montastruc J.L., et al. Chloroquine and hydroxychloroquine in the management of COVID-19: much kerfuffle but little evidence. Therapie. 2020;75:363–370. - PMC - PubMed
1. Saag M.S. Misguided use of hydroxychloroquine for COVID-19: the infusion of politics into science. JAMA. 2020;324:2161–2162. - PubMed
1. Perez J., Roustit M., Lepelley M., Revol B., Cracowski J.L., Khouri C. Reported adverse drug reactions associated with the use of hydroxychloroquine and chloroquine during the COVID-19 pandemic. Ann Intern Med. 2021;174:878–880. - PMC - PubMed